Drug Trial Radar · NCT04083339
Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy
Last checked: Nov 19, 2026Latest source record: Dec 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
675
Planned (sponsor's estimate)
Start
Sep 20, 2019
Primary completion
Dec 2023
Study completion Dec 2025
Sponsor
- Lead sponsor
- Applied Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, placebo-controlled, 2-part study to evaluate the safety and efficacy of AT-001 in adult patients (N=675) with Diabetic Cardiomyopathy at high risk of progression to overt heart failure.
Conditions
- Diabetic Cardiomyopathies
Interventions
AT-001Drug
AT-001 will be administered as 3 capsules twice daily, before breakfast and before dinner. At present AT001 is the sole name for the active substance. No INN/genetic name is available to date
PlaceboDrug
Matching placebo will be administered as 3 capsules twice daily, before breakfast and before dinner
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak VO2 during cardio-pulmonary exercise test (CPET);Time frame: 15 months after randomization]
Locations
79 sites in 10 countries. Site status is shown where the registry gives one.
Westside Medical Associates of Los Angeles
Beverly Hills, California
University of California, San Diego (UCSD)
La Jolla, California
Clinical Trials Research
Lincoln, California
University of California - Irvine Medical Center
Orange, California
Metabolic Institute of America
Tarzana, California
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Torrance, California
ALL Medical Research, LLC
Cooper City, Florida
New Generation of Medical Research
Hialeah, Florida
Broward Research Center
Pembroke Pines, Florida
Progressive Medical Research
Port Orange, Florida
UnityPoint Health - Methodist Hospital
Peoria, Illinois
Brigham and Women's Hospital
Boston, Massachusetts
Universty of Mississippi Medical Center
Jackson, Mississippi
St. Louis Heart and Vascular Cardiology
St Louis, Missouri
Chear Center LLC
The Bronx, New York
Montefiore Medical Center
The Bronx, New York
Cleveland Clinic
Cleveland, Ohio
Remington Davis, Inc.
Columbus, Ohio
South Oklahoma Heart Research
Oklahoma City, Oklahoma
Mountain View Clinical Research - Greer
Greer, South Carolina
Mountain View Clinical Research
Greer, South Carolina
Holston Medical Group
Kingsport, Tennessee
Dallas Diabetes Research Center
Dallas, Texas
Southwest Family Medicine Associates
Dallas, Texas
University of Texas Southwestern
Dallas, Texas
Juno Research, LLC - Northwest Site
Houston, Texas
Juno Research, LLC - Southwest Houston Site
Houston, Texas
FMC Science
Lampasas, Texas
Prince Charles Hospital
Chermside, Queensland, Australia
CORE Research Group Pty. Ltd.
Milton, Queensland, Australia
AusTrials
Taringa, Queensland, Australia
University of Tasmania at Hobart
Hobart, Tasmania, Australia
Barwon Health-University Hospital Geelong
Geelong, Victoria, Australia
Austin Health
Heidelberg, Victoria, Australia
Baker Heart and Diabetes Institute
Melbourne, Victoria, Australia
C-Endo - Endocrinology Centre
Calgary, Alberta, Canada
BC Diabetes
Vancouver, British Columbia, Canada
LMC Diabetes & Endocrinology Ltd. - Brampton
Brampton, Ontario, Canada
LMC Diabetes & Endocrinology Ltd. - Thornhill
Concord, Ontario, Canada
LMC Diabetes & Endocrinology Ltd. - Etobicoke
Etobicoke, Ontario, Canada
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.